Vertex Pharmaceuticals Issues 2026 Revenue Guidance of $13.15B-$13.25B
Vertex Pharmaceuticals (VRTX) reported strong third-quarter performance, characterized by a 12% year-on-year increase in total revenue. CEO Reshma Kewalramani noted that growth was well-balanced across both U.S. and international markets, driven primarily by the company's cystic fibrosis (CF) franchise. Looking ahead, the company provided long-term financial visibility by outlining 2026 revenue guidance in the range of $13.15 billion to $13.25 billion. This projection includes an additional $40 million to $50 million contribution from Crinetics. The results reflect continued commercial strength and steady advancement within the company's drug pipeline.
Topics: earnings pharmaceuticals quarterly results revenue growth
Read the full article at Seeking Alpha
Part of the story Pfizer Raises 2026 Revenue Guidance Amid Strong Growth in Acquired Products (18 articles)